

# COMMON PRIOR AUTHORIZATION CRITERIA

Although requirements vary by plan, below are the common criteria that may be requested for KRYSTEXXA. For payer-specific criteria, please contact your Patient Access Manager or **KRYSTEXXAConnect**.

## PATIENT IS COVERED BY APPROVED PRODUCT LABEL

- 1 Date of birth (adult patients only)
- 2 Lab results: G6PD\* (normal activity only)
- 3 Appropriate chronic gout diagnosis code
  - Use the enclosed coding wheel
  - Code for chronic gout due to renal impairment should only be used as a secondary diagnosis code

## PLANS MAY REQUIRE ADDITIONAL NOTES ON INSUFFICIENT EFFICACY OR TOLERABILITY

- ✓ Dates, dosage, and duration of treatment with xanthine oxidase inhibitors (allopurinol or febuxostat)
  - Include any medication side effects, if applicable
- ✓ Lab results: serum uric acid (sUA) levels throughout previous treatments
  - Reference American College of Rheumatology (ACR) Guidelines
- ✓ Number of gout flares in the last 18 months and/or number of visible tophi
  - Provide any relevant imaging results
  - If patient has visible tophi, use coding wheel to indicate location

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.<sup>1</sup>

## ACR Guidelines are a useful reference to benchmark an sUA goal for treatment

The guidelines recommend lowering to a minimum target of <6 mg/dL. However, an sUA target of <5 mg/dL is often required to durably improve signs and symptoms of gout.<sup>2</sup>

To reference the full ACR Guidelines, visit [www.KRYSTEXXAhcp.com](http://www.KRYSTEXXAhcp.com)

\*KRYSTEXXA is contraindicated in patients with G6PD deficiency. G6PD deficiency is an abnormally low level of glucose-6-phosphate dehydrogenase. Patients of African, Mediterranean, and Southern Asian ancestry have a higher risk of deficiency.<sup>1</sup> Providers are responsible for timely and accurate submission of prior authorization requests. Horizon Pharma does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Please see Important Safety Information on following page and click for [Full Prescribing Information](#) including Boxed Warning.

**KRYSTEXXA**  
pegloticase

# INDICATION AND IMPORTANT SAFETY INFORMATION

## INDICATIONS AND USAGE

KRYSTEXXA® (pegloticase) is indicated for the treatment of chronic gout in adult patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia.

## IMPORTANT SAFETY INFORMATION

### WARNING: ANAPHYLAXIS AND INFUSION REACTIONS

**Anaphylaxis and infusion reactions have been reported to occur during and after administration of KRYSTEXXA. Anaphylaxis may occur with any infusion, including a first infusion, and generally manifests within 2 hours of the infusion. However, delayed-type hypersensitivity reactions have also been reported. KRYSTEXXA should be administered in healthcare settings and by healthcare providers prepared to manage anaphylaxis and infusion reactions. Patients should be premedicated with antihistamines and corticosteroids. Patients should be closely monitored for an appropriate period of time for anaphylaxis after administration of KRYSTEXXA. Monitor serum uric acid levels prior to infusions and consider discontinuing treatment if levels increase to above 6 mg/dL, particularly when 2 consecutive levels above 6 mg/dL are observed.**

The risk of anaphylaxis and infusion reactions is higher in patients who have lost therapeutic response.

Concomitant use of KRYSTEXXA and oral urate-lowering agents may blunt the rise of sUA levels. Patients should discontinue oral urate-lowering agents and not institute therapy with oral urate-lowering agents while taking KRYSTEXXA.

In the event of anaphylaxis or infusion reaction, the infusion should be slowed, or stopped and restarted at a slower rate.

Inform patients of the symptoms and signs of anaphylaxis, and instruct them to seek immediate medical care should anaphylaxis occur after discharge from the healthcare setting.

### CONTRAINDICATIONS: G6PD DEFICIENCY ASSOCIATED HEMOLYSIS AND METHEMOGLOBINEMIA

**Screen patients for G6PD deficiency prior to starting KRYSTEXXA. Hemolysis and methemoglobinemia have been reported with KRYSTEXXA in patients with G6PD deficiency. Do not administer KRYSTEXXA to these patients.**

### GOUT FLARES

An increase in gout flares is frequently observed upon initiation of anti-hyperuricemic therapy, including treatment with KRYSTEXXA. If a gout flare occurs during treatment, KRYSTEXXA need not be discontinued. Gout flare prophylaxis with a non-steroidal anti-inflammatory drug (NSAID) or colchicine is recommended starting at least 1 week before initiation of KRYSTEXXA therapy and lasting at least 6 months, unless medically contraindicated or not tolerated.

### CONGESTIVE HEART FAILURE

KRYSTEXXA has not been studied in patients with congestive heart failure, but some patients in the clinical trials experienced exacerbation. Exercise caution when using KRYSTEXXA in patients who have congestive heart failure and monitor patients closely following infusion.

### ADVERSE REACTIONS

The most commonly reported adverse reactions in clinical trials with KRYSTEXXA are gout flares, infusion reactions, nausea, contusion or ecchymosis, nasopharyngitis, constipation, chest pain, anaphylaxis and vomiting.

To report SUSPECTED ADVERSE REACTIONS, contact Horizon Pharma Rheumatology LLC at 1-866-479-6742 or the FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

Please see **Full Prescribing Information**, including **Boxed Warning**.

**References:** 1. KRYSTEXXA [prescribing information]. Horizon Pharma Rheumatology LLC.  
2. Khanna D, et al. *Arthritis Care Res.* 2012;64:1431-1446.



KRYSTEXXA® is a registered trademark of Horizon Pharma Rheumatology LLC.  
© 2018 Horizon Pharma plc P-KRY-00776 (10/18)

